Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: The hidden face of estrogens

Journal of Clinical Oncology

Volumn 25, Issue 24, 2007, Pages 3596-3602

  Cussenot, Olivier ^a   Azzouzi, Abdel Rhamene ^b   Nicolaiew, Nathalie ^b   Fromont, Gaelle ^b   Mangin, Philippe ^b   Cormier, Luc ^b   Fournier, Georges ^b   Valeri, Antoine ^b   Lane, Stephane ^b   Thibault, Frederic ^b   Giordanella, Jean Pierre ^b   Pouchard, Michel ^b   Zheng, Yan ^b   Hamdy, Freddie C ^b   Cox, Angela ^b   Cancel Tassin, Geraldine ^b  

^a HÔPITAL TENON   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1B1; ESTROGEN;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ESTROGEN METABOLISM; FRANCE; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GENOTYPE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; ONSET AGE; PRIORITY JOURNAL; PROSTATE CANCER; STRATIFICATION;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE; ARYL HYDROCARBON HYDROXYLASES; CATECHOL O-METHYLTRANSFERASE; ESTROGENS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 34548502258     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.0908     Document Type: Article

References (40)

1. International Agency for Research on Cancer: CANCERMondial. http://www-dep.iarc.fr
2. Bill-Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984, 2005
3. Severi G, Morris HA, Maclnnis RJ, et al: Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15:86-91, 2006
4. Bosland MC: The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 39-66, 2000
5. Yuen MT, Leung LK, Wang J, et al: Enhanced induction of prostatic dysplasia and carcinoma in Noble rat model by combination of neonatal estrogen exposure and hormonal treatments at adulthood. Int J Oncol 27:1685-1695, 2005
6. Algarté-Génin M, Cussenot O, Costa P: Prevention of prostate cancer by androgens: Experimental paradox or clinical reality. Eur Urol 46:285-294, 2004; discussion 294-295
7. Ho SM: Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 91:491-503, 2004
8. Rogan EG, Cavalieri EL: Estrogen metabolites, conjugates, and DNA adducts: Possible biomarkers for risk of breast, prostate, and other human cancers. Adv Clin Chem 38:135-149, 2004
9. Cavalieri EL, Rogan EG: A unified mechanism in the initiation of cancer. Ann N Y Acad Sci 959: 341-354, 2002
10. Sharp L, Cardy AH, Cotton SC, et al: CYP17 gene polymorphisms: Prevalence and associations with hormone levels and related factors: A HuGE review. Am J Epidemiol 160:729-740, 2004
11. Latil AG, Azzouzi R, Cancel GS, et al: Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92:1130-1137, 2001
12. Modugno F, Weissfeld JL, Trump DL, et al: Allelic variants of aromatase and the androgen and estrogen receptors: Toward a multigenic model of prostate cancer risk. Clin Cancer Res 7:3092-3096, 2001
13. Li L, Cicek MS, Casey G, et al: No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol Biomarkers Prev 13:2280-2281, 2004
14. Suzuki K, Nakazato H, Matsui H, et al: Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population. Anticancer Res 23: 4941-4946, 2003
15. Suzuki K, Nakazato H, Matsui H, et al: Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population. Cancer 98:1411-1416, 2003
16. Fukatsu T, Hirokawa Y, Araki T, et al: Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 24:2431-2437, 2004
17. Douglas JA, Zuhlke KA, Beebe-Dimmer J, et al: Identifying susceptibility genes for prostate cancer-a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol Biomarkers Prev 14:2035-2039, 2005
18. Mononen N, Seppala EH, Duggal P, et al: Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 66:743-747, 2006
19. Nock NL, Cicek MS, Li L, et al: Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 27:1842-1848, 2006
20. Yeager M, Orr N, Hayes RB, et al: Genomewide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39:645-649, 2007
21. Tsuchiya N, Wang L, Suzuki H, et al: Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24:1982-1989, 2006
22. Low YL, Taylor JI, Grace PB, et al: Polymorphisms in the CYP19 gene may affect the positive correlations between serum and urine phytoestrogen metabolites and plasma androgen concentrations in men. J Nutr 135:2680-2686, 2005
23. Feigelson HS, Ross RK, Yu MC, et al: Genetic susceptibility to cancer from exogenous and endogenous exposures. J Cell Biochem Suppl 25:15-22, 1996
24. Ntais C, Polycarpou A, loannidis JP: Association of the CYP17 gene polymorphism with the risk of prostate cancer: A meta-analysis. Cancer Epidemiol Biomarkers Prev 12:120-126, 2003
25. Vesovic Z, Herkommer K, Vogel W, et al: Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany. Anticancer Res 25:1303-1307, 2005
26. Forrest MS, Edwards SM, Houlston R, et al: Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis 8:95-102, 2005
27. Gennari L, Masi L, Merloni D, et al: A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: Effects on bone metabolism. J Clin Endocrinol Metab 89: 2803-2810, 2004
28. Siddiqui SA, Inman BA, Sengupta S, et al: Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer 107:521-529, 2006
29. Freedland SJ, Terris MK, Platz EA, et al: Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology 66:108-113, 2005
30. Amling CL, Riffenburgh RH, Sun L, et al: Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22: 439-445, 2004
31. Sissung TM, Price DK, Sparreboom A, et al: Pharmacogenetics and regulation of human cytochrome P450 1B1: Implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 4:135-150, 2006
32. Ragavan N, Hewitt R, Cooper LJ, et al: CYP1B1 expression in prostate is higher in the peripheral than in the transition zone. Cancer Lett 215:69-78, 2004
33. Ragavan N, Hewitt R, Hindley AC, et al: Expression of hormone-carcinogen-metabolising enzymes in the prostate: Clues into peripheral-zone susceptibility? Eur Urol 5:165, 2006 (suppl)
34. Zheng W, Xie DW, Jin F, et al: Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9:147-150, 2000
35. Lavigne JA, Helzlsouer KJ, Huang HY, et al: An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 57:5493-5497, 1997
36. Suzuki M, Mamun MR, Hara K, et al: The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate. Eur Urol 48: 752-759, 2005
37. Tanaka Y, Sasaki M, Shiina H, et al: Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 15:238-244, 2006
38. Tang YM, Green BL, Chen GF, et al: Human CYP1B1 Leu432Val gene polymorphism: Ethnic distribution in African-Americans, Caucasians and Chinese: oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 10:761-766, 2000
39. Cicek MS, Liu X, Casey G, et al: Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 14: 2173-2177, 2005
40. Sobti RC, Onsory K, Al-Badran Al, et al: CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol 25:287-294, 2006